Unprofitable companies can burn through cash quickly, leaving investors exposed if they fail to turn things around. Without a clear path to profitability, these businesses risk running out of capital or relying on dilutive fundraising.
Finding the right unprofitable companies is difficult, which is why we started StockStory — to help you navigate the market. Keeping that in mind, here is one unprofitable company with the potential to become an industry leader and two best left off your radar.
Two Stocks to Sell:
Enovis (ENOV)
Trailing 12-Month GAAP Operating Margin: -45.1%
With a focus on helping patients regain or maintain their natural motion, Enovis (NYSE:ENOV) develops and manufactures medical devices for orthopedic care, from injury prevention and pain management to joint replacement and rehabilitation.
Why Are We Bearish on ENOV?
-
Sales stagnated over the last five years and signal the need for new growth strategies
-
Earnings per share fell by 9.5% annually over the last five years while its revenue was flat, showing each sale was less profitable
-
Waning returns on capital from an already weak starting point displays the inefficacy of management’s past and current investment decisions
Enovis is trading at $20.69 per share, or 5.6x forward P/E. Dive into our free research report to see why there are better opportunities than ENOV.
AdaptHealth (AHCO)
Trailing 12-Month GAAP Operating Margin: -5%
With a network of approximately 680 locations serving patients across all 50 states, AdaptHealth (NASDAQ:AHCO) provides home medical equipment, supplies, and related services to patients with chronic conditions like sleep apnea, diabetes, and respiratory disorders.
Why Is AHCO Risky?
-
Annual sales declines of 2.7% for the past two years show its products and services struggled to connect with the market during this cycle
-
Falling earnings per share over the last five years has some investors worried as stock prices ultimately follow EPS over the long term
-
Low returns on capital reflect management’s struggle to allocate funds effectively, and its shrinking returns suggest its past profit sources are losing steam
AdaptHealth’s stock price of $6.02 implies a valuation ratio of 5.3x forward EV-to-EBITDA. To fully understand why you should be careful with AHCO, check out our full research report (it’s free).
One Stock to Buy:
Rocket Lab (RKLB)
Trailing 12-Month GAAP Operating Margin: -29.1%
Becoming the first private company in the Southern Hemisphere to reach space, Rocket Lab (NASDAQ:RKLB) offers rockets designed for launching small satellites.
